TRIUS THERAPEUTICS - Partnering or Buy Out = Upside
Positive top line data of Tedizolid (oral/IV, 2nd-generation oxazolidinone, PhIII, Acute Bacterial Skin and Skin Structure Infections – ABSSSI; PhII, CAP/HAP/Bacteremia, partnered with Bayer for Asian, LA and ME rights) from 2nd pivotal PhIII study (ESTABLISH 2, Table 1A/1B) increases the probability of approval by 1H14 in US in ABSSSI indication. We expect Tedizolid to achieve switching from Zyvox (intolerant, deep tissue infections where long term treatment is required – pulmonary setting etc) and vancomycin (non-responsive and renal impaired). Partnership/Acquisition could happen despite threat by generic Zyvox as the demand of new and potent antibiotics is growing due to ... For more detail, please read our initiation report released on 26th March, 2013 on Trius (TSRX) titled “Partnering or Buy Out = Upside”
Companies mentioned
Trius Therapeutics
Companies mentioned
Trius Therapeutics
